Chapter 1542: Nothing Left To Discuss
“Roxanne possesses the technology; the Damaris family’s medicinal herbs yielded only one batch of medicine. If you’re dissatisfied with the profit split, that’s fine. The profits from this batch, using your herbs, can be divided as you wish. However, the research institute retains the right to contract solely for this batch.”
Lucian slowed his speech. “This means, after this batch is sold, Roxanne can find another herb supplier, as she holds the manufacturing technology. But can Damaris Group find another research institute to produce this medicine?”
His words highlighted the institute’s advantageous position. Damaris Group wasn't Roxanne's only option; conversely, Damaris Group relied solely on Roxanne. Therefore, the research institute should have held the dominant position from the outset. Jack's decision now lay between long-term, stable returns or high short-term profit.
Jack hadn't anticipated Lucian's maneuver. He met Lucian’s gaze impassively, then addressed Roxanne. “Ms. Jarvis, are you certain you wish to negotiate this collaboration solely on a business basis? Do you view Damaris Group as merely a disposable asset?”
She glanced at Lucian, who nodded. Roxanne considered this, then remained silent, lips pursed.
Lucian stated firmly, “There are no friends in business. Mr. Damaris, you should understand this better than Roxanne. Profit division is always the most contentious aspect. Aren't you attempting to manipulate Roxanne’s emotions with appeals to friendship, forcing an unfair concession?”
Jack’s negotiating skills paled in comparison to Lucian's. His face contorted with anger. After a silent moment, he said stiffly, “I cannot accept this profit division.”
Lucian responded, “Perhaps I should show you Farwell Group's profit-sharing arrangements when we control the technology. You might find the current offer acceptable then.”
This implied that under Lucian's management, the Damaris family's share would decrease further. The friendly façade on Jack’s face vanished, replaced by a grim expression.
“If you accept my offer, we sign now. If not, our institute will hire a third party to evaluate Damaris Group’s contribution and compensate you tenfold,” Roxanne said, sliding the agreement toward him.
Without looking, Jack tore it in half and threw it back. Roxanne was startled. Jack had always presented a gentlemanly demeanor; as heir to a prominent traditional medicine family, she assumed he’d maintain a polite façade. His impulsiveness surprised her.
Tension filled the office.
“If I recall correctly,” Jack said, “we agreed to share the patent and profits equally. Your unilateral alteration leaves no room for discussion.”
Roxanne frowned. “You also promised access to medical texts. I agreed to share the patent because of that. However, I received no such texts and developed this technology independently. I have no reason to share the patent.”